NautaDutilh assists Thermo Fisher with its recommended public offer for the shares in QIAGEN, which are listed on the New York Stock Exchange and the Frankfurt Stock Exchange. The transaction represents a value of approximately EUR 10.4 billion. This is Thermo Fisher's second public offer for a listed Dutch company in 3 years' time, following its $ 7 billion acquisition of Patheon in 2017.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN (NYSE: QGEN; FWB: QIA), a leading global provider of molecular diagnostics and sample preparations technologies, announced that their boards have unanimously approved Thermo Fisher's acquisition of QIAGEN.
Thermo Fisher will commence a tender offer to acquire all of the issued ordinary shares of QIAGEN for EUR 39 per share in cash. The transaction represents an enterprise value of approximately EUR 10.4 billion. The transaction is subject to the satisfaction of customary closing conditions.
NautaDutilh's team advising Thermo Fisher was led by Leo Groothuis and Stefan Wissing and further consisted of Paul van der Bijl, Sanne Mesu, Chris Warner, Nina Kielman, Sybren de Beurs, Ernst van der Touw and Alex Draaisma. NautaDutilh worked closely together with Wachtell, Lipton, Rosen & Katz as US counsel and Hengeler Mueller as German counsel.